New study tracks eplontersen safety in pregnancy and breastfeeding
NCT ID NCT07205666
First seen Oct 31, 2025 · Last updated May 21, 2026 · Updated 30 times
Summary
This study watches for health problems in pregnant or breastfeeding women who have taken eplontersen for transthyretin amyloidosis, and in their babies up to one year old. It does not give any treatment—it only collects information from real-world cases. The goal is to better understand any risks to the mother, fetus, or infant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOIDOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGFrankfurt, Germany
Conditions
Explore the condition pages connected to this study.